BPIM
CRL icon

Brant Point Investment Management’s Charles River Laboratories CRL Stock Holding History

Brant Point Investment Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-100
Closed -$2.36M – 106
2023
Q4 		$2.36M Hold
100
– – 0.19% 86
2023
Q3 		$1.96M Buy
+100
New +$20.5K 0.18% 82

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Brant Point Investment Management's CRL Position: Q1 2024 in Review

Brant Point Investment Management sold out of Charles River Laboratories (CRL) in Q1 2024, closing a stake of 11,936 shares — an estimated $2.82M sold.

Brant Point Investment Management first reported a position in CRL in Q1 2017 and held it in 19 quarters. The position peaked at $6.25M in Q1 2022. 677 funds tracked by Wall St. Rank hold CRL as of Q1 2024.

  • Brant Point Investment Management reported no remaining Charles River Laboratories position as of Q1 2024 after selling out during the quarter.
  • Brant Point Investment Management sold 11,936 Charles River Laboratories shares in Q1 2024, an estimated $2.82M.
  • Brant Point Investment Management first reported a position in Charles River Laboratories in Q1 2017 and held it in 19 quarters.
  • Brant Point Investment Management's Charles River Laboratories position peaked at $6.25M in Q1 2022.
  • 677 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2024.

Based on Brant Point Investment Management's 13F filing for Q1 2024, filed 14 May 2024.